Pneumococcal vaccines: Do they prevent infection and how?

Current Opinion in Infectious Diseases

Volumn 17, Issue 3, 2004, Pages 177-184

  Posfay Barbe, Klara M ^a   Wald, Ellen R ^a  

^a CHILDREN S HOSPITAL OF PITTSBURGH   (United States)

Author keywords

Acute otitis media; Pneumococcal conjugate vaccines; Streptococcus pneumoniae; Vaccines

Indexed keywords

PNEUMOCOCCUS VACCINE;

BACTEREMIA; CLINICAL TRIAL; DISEASE TRANSMISSION; DRUG EFFICACY; HUMAN; OTITIS MEDIA; PNEUMONIA; PREVALENCE; RESPIRATORY TRACT DISEASE; REVIEW; SEROTYPE; STREPTOCOCCUS INFECTION; STREPTOCOCCUS PNEUMONIAE; UNITED STATES;

ACUTE DISEASE; AGED; AGED, 80 AND OVER; CHILD, PRESCHOOL; HUMANS; IMMUNOCOMPROMISED HOST; INFANT; MENINGOCOCCAL VACCINES; OTITIS MEDIA; PNEUMOCOCCAL INFECTIONS; PNEUMOCOCCAL VACCINES; STREPTOCOCCUS PNEUMONIAE; TREATMENT OUTCOME; VACCINATION;

EID: 2542519906     PISSN: 09517375     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001432-200406000-00002     Document Type: Review

References (57)

1. Feikin DR, Schuchat A, Kolczak M, et al. Mortality from invasive pneumococcal pneumonia in the era of antibiotic resistance, 1995-1997. Am J Public Health 2000; 90:223-229.
2. Robinson KA, Baughman W, Rothrock G, et al. Epidemiology of invasive Streptococcus pneumoniae infections in the United States, 1995-1998: opportunities for prevention in the conjugate vaccine era. JAMA 2001; 285:1729-1735.
3. Centers for Disease Control and Prevention. Preventing pneumococcal disease among infants and young children. Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2000; 49:1-35.
4. Schwartz B, Bell DM, Hughes JM. Preventing the emergence of antimicrobial resistance. A call for action by clinicians, public health officials, and patients. JAMA 1997; 278:944-945.
5. Breiman RF, Butler JC, Tenover FC, et al. Emergence of drug-resistant pneumococcal infections in the United States. JAMA 1994; 271:1831-1835.
6. Whitney CG, Farley MM, Hadler J, et al. Increasing prevalence of multidrug-resistant Streptococcus pneumoniae in the United States. N Engl J Med 2000; 343:1917-1924.
7. Black S, Shinefield H, Fireman B, et al. Efficacy, safety and immunogenicity of heptavalent pneumococcal conjugate vaccine in children. Northern California Kaiser Permanente Vaccine Study Center Group. Pediatr Infect Dis J 2000; 19:187-195.
8. Jakobsen H, Jonsdottir I. Mucosal vaccination against encapsulated respiratory bacteria - new potentials for conjugate vaccines? Scand J Immunol 2003; 58:119-128.
9. Pelton SI, Dagan R, Gaines BM, et al. Pneumococcal conjugate vaccines: proceedings from an interactive symposium at the 41st Interscience Conference on Antimicrobial Agents and Chemotherapy. Vaccine 2003; 21:1562-1571.
10. Lin PL, Michaels MG, Janosky J, et al. Incidence of invasive pneumococcal disease in children 3 to 36 months of age at a tertiary care pediatric center 2 years after licensure of the pneumococcal conjugate vaccine. Pediatrics 2003; 111:896-899. A decrease in invasive pneumococcal infections after licensure of PCV7 was documented in a large children's hospital.
11. Whitney CG, Farley MM, Hadler J, et al. Decline in invasive pneumococcal disease after the introduction of protein-polysaccharide conjugate vaccine. N Engl J Med 2003; 348:1737-1746. A large population-based study demonstrated a remarkable decline in cases of invasive pneumococcal disease throughout the US. The decrease in the number of cases was most dramatic in children younger than 5 years of age, but was observed in non-vaccinated adults as well.
12. Dagan R, Givon-Lavi N, Zamir O, et al. Reduction of nasopharyngeal carriage of Streptococcus pneumoniae after administration of a 9-valent pneumococcal conjugate vaccine to toddlers attending day care centers. J Infect Dis 2002; 185:927-936.
13. Mbelle N, Huebner RE, Wasas AD, et al. Immunogenicity and impact on nasopharyngeal carriage of a nonavalent pneumococcal conjugate vaccine. J Infect Dis 1999; 180:1171-1176.
14. Obaro SK, Adegbola RA, Banya WA, Greenwood BM. Carriage of pneumococci after pneumococcal vaccination. Lancet 1996; 348:271-272.
15. Finkelstein JA, Huang SS, Daniel J, et al. Antibiotic-resistant Streptococcus pneumoniae in the heptavalent pneumococcal conjugate vaccine era: predictors of carriage in a multicommunity sample. Pediatrics 2003; 112:862-869.
16. Jacobs MR, Felmingham D, Appelbaum PC, Gruneberg RN. The Alexander Project 1998-2000: susceptibility of pathogens isolated from community-acquired respiratory tract infection to commonly used antimicrobial agents. J Antimicrob Chemother 2003; 52:229-246.
17. Nowalk MP, Middleton DB, Zimmerman RK, et al. Increasing pneumococcal vaccination rates among hospitalized patients. Infect Control Hosp Epidemiol 2003; 24:526-531.
18. Fireman B, Black SB, Shinefield HR, et al. Impact of the pneumococcal conjugate vaccine on otitis media. Pediatr Infect Dis J 2003; 22:10-16.
19. Eskola J, Kilpi T, Palmu A, et al. Efficacy of a pneumococcal conjugate vaccine against acute otitis media. N Engl J Med 2001; 344:403-409.
20. Kilpi T, Ahman H, Jokinen J, et al. Protective efficacy of a second pneumococcal conjugate vaccine against pneumococcal acute otitis media in infants and children: randomized, controlled trial of a 7-valent pneumococcal polysaccharide-meningococcal outer membrane protein complex conjugate vaccine in 1666 children. Clin Infect Dis 2003; 37:1155-1164. This prospective controlled clinical trial showed a heptavalent pneumococcal polysaccharide-meningococcal outer membrane complex conjugate vaccine to have a 56% efficacy in protecting against episodes of AOM due to S. pneumoniae. Protection occurred after the second dose but did not extend to the non-vaccine serotypes contained in the serogroups found in the vaccine.
21. McEllistrem MC, Adams J, Mason EO, Wald ER. Epidemiology of acute otitis media caused by Streptococcus pneumoniae before and after licensure of the 7-valent pneumococcal protein conjugate vaccine. J Infect Dis 2003; 188:1679-1684. Middle-ear isolates obtained from children with AOM before and after licensure of the pneumococcal vaccine were examined. The proportion of non-vaccine serotypes causing infection increased substantially after licensure of the vaccine in children who had received at least two doses of vaccine. Capsular switching was documented.
22. Coffey TJ, Daniels M, Enright MC, Spratt BG. Serotype 14 variants of the Spanish penicillin-resistant serotype 9V clone of Streptococcus pneumoniae arose by large recombinational replacements of the cpsA-pbp1a region. Microbiology 1999; 145 (Pt 8):2023-2031.
23. Coffey TJ, Enright MC, Daniels M, et al. Recombinational exchanges at the capsular polysaccharide biosynthetic locus lead to frequent serotype changes among natural isolates of Streptococcus pneumoniae. Mol Microbiol 1998; 27:73-83.
24. Facklam RR, Breiman RF. Current trends in bacterial respiratory pathogens. Am J Med 1991; 91:3S-11S.
25. Black SB, Shinefield HR, Ling S, et al. Effectiveness of heptavalent pneumococcal conjugate vaccine in children younger than five years of age for prevention of pneumonia. Pediatr Infect Dis J 2002; 21:810-815.
26. Zhao GM, Black S, Shinefield H, et al. Serotype distribution and antimicrobial resistance patterns in Streptococcus pneumoniae isolates from hospitalized pediatric patients with respiratory infections in Shanghai, China. Pediatr Infect Dis J 2003; 22:739-742.
27. Bennett D, Lennon B, Humphreys H, Cafferkey M. Penicillin susceptibility and epidemiological typing of invasive pneumococcal isolates in the Republic of Ireland. J Clin Microbiol 2003; 41:3641-3648.
28. Gertz RE Jr, McEllistrem MC, Boxrud DJ, et al. Clonal distribution of invasive pneumococcal isolates from children and selected adults in the United States prior to 7-valent conjugate vaccine introduction. J Clin Microbiol 2003; 41:4194-4216.
29. Muhlemann K, Matter HC, Tauber MG, Bodmer T. Nationwide surveillance of nasopharyngeal Streptococcus pneumoniae isolates from children with respiratory infection, Switzerland, 1998-1999. J Infect Dis 2003; 187:589-596.
30. Dobay O, Rozgonyi F, Hajdu E, et al. Antibiotic susceptibility and serotypes of Streptococcus pneumoniae isolates from Hungary. J Antimicrob Chemother 2003; 51:887-893.
31. Brandileone MC, de Andrade AL, Di Fabio JL, et al. Appropriateness of a pneumococcal conjugate vaccine in Brazil: potential impact of age and clinical diagnosis, with emphasis on meningitis. J Infect Dis 2003; 187:1206-1212.
32. Gordon SB, Kanyanda S, Walsh AL, et al. Poor potential coverage for 7-valent pneumococcal conjugate vaccine, Malawi. Emerg Infect Dis 2003; 9:747-749.
33. Gordon MA, Walsh AL, Chaponda M, et al. Bacteraemia and mortality among adult medical admissions in Malawi - predominance of non-typhi salmonellae and Streptococcus pneumoniae. J Infect 2001; 42:44-49.
34. Feikin DR, Davis M, Nwanyanwu OC, et al. Antibiotic resistance and serotype distribution of Streptococcus pneumoniae colonizing rural Malawian children. Pediatr Infect Dis J 2003; 22:564-567.
35. No authors listed. Prevention of pneumococcal disease: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 1997; 46:1-24.
36. Kumar D, Rotstein C, Miyata G, et al. Randomized, double-blind, controlled trial of pneumococcal vaccination in renal transplant recipients. J Infect Dis 2003; 187:1639-1645.
37. Molrine DC. Recommendations for immunizations in stem cell transplantation. Pediatr Transplant 2003; 7 (Suppl 3):76-85.
38. Molrine DC, Hibberd PL. Vaccines for transplant recipients. Infect Dis Clin North Am 2001; 15:273-305, xii.
39. Molrine DC, Antin JH, Guinan EC, et al. Donor immunization with pneumococcal conjugate vaccine and early protective antibody responses following allogeneic hematopoietic cell transplantation. Blood 2003; 101:831-836. Hematopoietic cell donors were immunized with heptavalent pneumococcal vaccine before transplantation. All recipients received three doses of vaccine after transplantation; 77% of the recipients with vaccinated donors had protective IgG levels after the first dose compared with only 36% in those who did not receive vaccination before transplantation.
40. Breiman RF, Keller DW, Phelan MA, et al. Evaluation of effectiveness of the 23-valent pneumococcal capsular polysaccharide vaccine for HIV-infected patients. Arch Intern Med 2000; 160:2633-2638.
41. Fry AM, Facklam RR, Whitney CG, et al. Multistate evaluation of invasive pneumococcal diseases in adults with human immunodeficiency virus infection: serotype and antimicrobial resistance patterns in the United States. J Infect Dis 2003; 188:643-652.
42. Klugman KP, Madhi SA, Huebner RE, et al. A trial of a 9-valent pneumococcal conjugate vaccine in children with and those without HIV infection. N Engl J Med 2003; 349:1341-1348. In this large, randomized, double-blind study, almost 20 000 children received a 9-valent conjugated pneumococcal vaccine. It reduced the incidence of pneumonia, as well as the incidence of vaccine-serotype invasive disease both in HIV-infected and non-infected patients.
43. Subramaniam KS, Segal R, Lyles RH, et al. Qualitative change in antibody responses of human immunodeficiency virus-infected individuals to pneumococcal capsular polysaccharide vaccination associated with highly active antiretroviral therapy. J Infect Dis 2003; 187:758-768.
44. Butler JC, Hofmann J, Cetron MS, et al. The continued emergence of drug-resistant Streptococcus pneumoniae in the United States: an update from the Centers for Disease Control and Prevention's Pneumococcal Sentinel Surveillance System. J Infect Dis 1996; 174:986-993.
45. Jackson LA, Neuzil KM, Yu O, et al. Effectiveness of pneumococcal polysaccharide vaccine in older adults. N Engl J Med 2003; 348:1747-1755. This retrospective study reports the efficacy of pneumococcal vaccine in preventing S. pneumoniae bacteremia in the elderly, but could not show a decrease in the rate of pneumonia.
46. Artz AS, Ershler WB, Longo DL. Pneumococcal vaccination and revaccination of older adults. Clin Microbiol Rev 2003; 16:308-318.
47. Influenza and pneumococcal vaccination levels among persons aged ≥65 years - United States, 1999. MMWR Morb Mortal Wkly Rep 2004; 25:532-537.
48. Zimmerman RK, Santibanez TA, Fine MJ, et al. Barriers and facilitators of pneumococcal vaccination among the elderly. Vaccine 2003; 21:1510-1517.
49. Wong-Beringer A, Brodetsky E, Quist R. Pneumococcal vaccination in hospitalized elderly patients: role of the pharmacist. Pharmacotherapy 2003; 23:199-208.
50. Hoffman JA, Mason EO, Schutze GE, et al. Streptococcus pneumoniae infections in the neonate. Pediatrics 2003; 112:1095-1102.
51. Pneumococcal vaccination for cochlear implant candidates and recipients: updated recommendations of the Advisory Committee on Immunization Practices. MMWR Morb Mortal Wkly Rep 2003; 52:739-740.
52. Bluestone CD. Prevention of meningitis: cochlear implants and inner ear abnormalities. Arch Otolaryngol Head Neck Surg 2003; 129:279-281.
53. Quiambao BP, Nohynek H, Kayhty H, et al. Maternal immunization with pneumococcal polysaccharide vaccine in the Philippines. Vaccine 2003; 21:3451-3454.
54. Lynch JM, Briles DE, Metzger DW. Increased protection against pneumococcal disease by mucosal administration of conjugate vaccine plus interleukin-12. Infect Immun 2003; 71:4780-4788.
55. Binder CJ, Horkko S, Dewan A, et al. Pneumococcal vaccination decreases atherosclerotic lesion formation: molecular mimicry between Streptococcus pneumoniae and oxidized LDL. Nat Med 2003; 9:736-743.
56. Puumalainen T, Dagan R, Wuorimaa T, et al. Greater antibody responses to an eleven valent mixed carrier diphtheria- or tetanus-conjugated pneumococcal vaccine in Filipino than in Finnish or Israeli infants. Pediatr Infect Dis J 2003; 22:141-149.
57. Puumalainen T, Ekstrom N, Zeta-Capeding R, et al. Functional antibodies elicited by an 11-valent diphtheria-tetanus toxoid-conjugated pneumococcal vaccine. J Infect Dis 2003; 187:1704-1708. This study tries to evaluate not only the quantitative, but also the qualitative, response to an 11-valent conjugated pneumococcal vaccine by using an opsonophagocytic assay. It determines antibody concentrations required to kill pneumococci in vitro, but cannot be used to extrapolate protection against pneumococcal infection.